Inhibition of KIF14 Suppresses Tumor Cell Growth and Promotes Apoptosis in Human Glioblastoma

Wei Huang\textsuperscript{a,b}  JunYu Wang\textsuperscript{b}  Danfeng Zhang\textsuperscript{b}  Wen Chen\textsuperscript{b}  Lijun Hou\textsuperscript{b}  Xiaojun Wu\textsuperscript{b}  Yicheng Lu\textsuperscript{b}

\textsuperscript{a}Department of Neurosurgery, Kunming general Hospital, PLA, Kunming, \textsuperscript{b}Department of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China

Key Words
KIF14 • Astrocytoma • Cell cycle • Apoptosis • AKT

Abstract

\textbf{Background/Aims:} The mitotic kinesin superfamily protein KIF14 is essential for cytokinesis and chromosome segregation, and increased KIF14 expression is related to a variety of human cancers. However, the role of KIF14 in the development and malignant progression of astrocytomas and the underlying mechanisms remain unclear. The present study examined the relation between KIF14 and the pathogenesis of malignant astrocytoma.

\textbf{Methods and Results:} The role of KIF14 in astrocytoma development and progression was investigated by analyzing KIF14 expression using SYBR Green quantitative real-time RT-PCR, western blotting and immunohistochemistry in human astrocytoma and normal brain tissues. KIF14 expression was higher in astrocytoma samples, and was positively correlated with pathological grade and proliferative activity indicated by Ki-67 staining. SiRNA knockdown of KIF14 inhibited tumor growth \textit{in vitro} and \textit{in vivo}, attenuated anchorage-independent growth, and induced G2/M phase arrest, cytokinesis failure and apoptosis in glioblastoma cell lines in association with decreased AKT phosphorylation and activity.

\textbf{Conclusions:} The upregulation of KIF14 in astrocytoma is associated with disease severity, and suppression of KIF14 inhibits cell proliferation and induces apoptosis through a mechanism involving the inactivation of AKT signaling, suggesting that KIF14 plays an important role in astrocytoma tumorigenesis and could be a promising molecular target for anticancer therapy.

W. Huang, J. Wang and D. Zhang contributed equally to this work.
Introduction

Astrocytic gliomas are the most common cerebral neoplasms, accounting for approximately 80% of primary malignant tumors of the central nervous system (CNS) [1]. They are divided into four histological grades with different clinical behaviors according to the World Health Organization (WHO) classification: low-grade astrocytomas (grade II), anaplastic astrocytomas (grade III), and glioblastoma (GBM, grade IV), which is the most prevalent and aggressive form of glioma [2]. The current treatment of gliomas includes surgical resection and radiotherapy in combination with adjuvant chemotherapy. However, the prognosis of patients with glioma is poor, and the median overall survival of patients with GBM is 12–15 months, with only 3–5% of patients surviving more than 3 years [3]. The recurrence rate of GBM is almost 100%, and patients with recurrent GBM have a median survival of 5–7 months [4]. The cell(s) of origin for the formation of gliomas is currently unknown. One major theory postulates that neural stem cells or neural progenitors undergo transformation when they are in a transit-amplifying phase of development [5, 6].

Kinesin superfamily proteins (KIFs) are a conserved class of microtubule-dependent molecular motor proteins that function in the transport of organelles, proteins and mRNA in an ATP-dependent manner. More than 45 KIFs have been described in mice and mammals and they are divided into 15 families that are grouped into three types depending on the position of the motor domain, namely N, M and C kinesins [7, 8]. KIF14, an N-type kinesin belong to the kinesin-3 superfamily [9], is a cytoskeletal protein that plays a role in mitotic spindle formation [10], chromosome segregation [11] and cytokinesis completion [12, 13]. Silencing of KIF14 results in alterations in the cell cycle, suggesting that KIF14 plays a role in oncogenesis [14]. KIF14 is overexpressed in several malignancies including hepatocellular and laryngeal carcinomas, and ovarian cancer, and its expression is associated with chemo resistance in triple-negative breast cancer [15-17]. Besides, it is found that KIF14 expression in gliomas is tumor-specific and increased in more aggressive tumors [18].

In the present study, we showed that KIF14 is overexpressed in human malignant astrocytomas and associated with tumor grade. Suppression of KIF14 expression not only inhibited cell growth, clonogenic potential and induced G2/M phase arrest and apoptosis in glioblastoma cell lines, but also inhibited tumor growth in vivo, suggesting that KIF14 plays an important role in astrocytoma tumorigenesis and could be a promising molecular target for anticancer therapy.

Materials and Methods

**Tumor samples and cell culture**

Human primary astrocytoma samples were collected by surgical resection at the Department of Neurosurgery of Changzheng Hospital and then divided to two parts. One part was snap frozen at -80°C, and the other part was stored in RNAlater (Ambion, Austin, TX, USA) at -20°C for RNA extraction. Tumors were classified and graded according to the WHO grading system after histopathological analyses. 7 pilocytic astrocytomas (PA, WHO grade I), 15 diffuse astrocytomas (DA, WHO grade II), 9 anaplastic astrocytomas (AA, WHO grade III), and 22 glioblastomas (GBM, WHO grade IV) were surgically resected between 2000 and 2008. The clinicopathological features of all the patients were indicated in Table 1. Normal human brain tissues were obtained from five individuals who had undergone decompressive craniectomy and had no prior pathological conditions. All specimens were examined and stored by the Changzheng Hospital Institutional Review Board. The study was reviewed and approved by the Institutional Review Board of the ShangHai Second Military Medical University, in accordance with the policies of its Ethics Committee. Written informed consent was obtained from all participating patients and all clinical and histopathological data provided to the researchers were rendered anonymous.

The glioblastoma cell lines U373, U251, U138 and U87 were purchased from American Tissue Culture Collection (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS (Gibco, Grand Island, NY) at 37°C and 5% CO₂ in a humidified chamber. Normal human
astrocytes (NHA) from Clonetics primary cell systems (Lonza, Basel, Switzerland) were cultured in astrocyte basal medium supplemented with the EGM SingleQuots (Lonza).

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded, 3 μm tissue sections were deparaffinized in xylol and rehydrated in a graded ethanol series. Antigen retrieval was performed by the microwave heating method for 20 min with Tris-EDTA buffer (10 mM Tris-HCl, pH 9.0; 1 mM EDTA). Endogenous peroxidase activity was eliminated by incubation with 3% methanolic hydrogen peroxide solution for 30 min. The slides were incubated in nonimmune serum for 30 min. Rabbit anti-KIF14 polyclonal antibody (ab71155, 1:1,000; Abcam, Cambridge, UK) and anti-Ki-67 primary antibody (ab15580; 1:200; Abcam) were added and the sections were incubated overnight at 4°C. After washing in TBST (150 mM NaCl, 10 mM Tris-HCl (pH 7.6), 0.1% Tween 20), the sections were incubated with biotin-conjugated secondary antibody for 20 min at room temperature, followed by peroxidase-conjugated biotin-streptavidin complex (Dako, Glostrup, Denmark) for 20 min, and finally visualized with 3, 3’-diaminobenzidine and counterstained with hematoxylin. To ensure the specificity of the immunostaining, sections in which the primary antibody was replaced by nonimmune serum were used as a negative control.

**Real-time qPCR analysis**

Total RNA was isolated from human astrocytoma tissues preserved in RNAlater (Ambion) using the RNeasy kit according to the manufacturer’s protocol (Qiagen, Valencia, CA, USA). Briefly, first-strand cDNA was reverse-transcribed from 1 μg total RNA using the Super-Script First-Strand cDNA System (Invitrogen, Carlsbad, CA, USA), and amplified by Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen). A master mix was prepared for each PCR reaction, which included Platinum SYBR Green qPCR SuperMix-UDG, forward primer, reverse primer and 10 ng of template cDNA. PCR conditions were 5 min at 95°C, followed by 50 cycles at 95°C for 15 s and 60°C for 1 min and 72°C for 30 s. The forward and reverse primer sequences for KIF14 were 5’-TGG TGA AAT GCC CTG TAC T-3’ and 5’-GGC AAC CAG TTA ACC CTT G-3’. The primer

### Table 1. Association of KIF14 expression in human glioma tissues with different clinicopathological features. WHO = World Health Organization, KPS = Karnofsky Performance Scale, NS = not significant

<table>
<thead>
<tr>
<th>Clinicopathological features</th>
<th>No. of cases</th>
<th>KIF14 expression</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>High (n, %)</td>
<td>Low (n, %)</td>
<td></td>
</tr>
<tr>
<td>WHO grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>7</td>
<td>2 (28.6)</td>
<td>5 (71.4)</td>
</tr>
<tr>
<td>II</td>
<td>15</td>
<td>8 (53.3)</td>
<td>7 (46.7)</td>
</tr>
<tr>
<td>III</td>
<td>9</td>
<td>8 (88.9)</td>
<td>1 (11.1)</td>
</tr>
<tr>
<td>IV</td>
<td>22</td>
<td>22 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;55</td>
<td>23</td>
<td>17 (73.9)</td>
<td>6 (26.1)</td>
</tr>
<tr>
<td>≥55</td>
<td>30</td>
<td>23 (76.7)</td>
<td>7 (23.3)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>32</td>
<td>25 (78.1)</td>
<td>7 (21.9)</td>
</tr>
<tr>
<td>Female</td>
<td>21</td>
<td>15 (71.4)</td>
<td>6 (28.6)</td>
</tr>
<tr>
<td>KPS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;80</td>
<td>29</td>
<td>26 (89.7)</td>
<td>3 (10.3)</td>
</tr>
<tr>
<td>≥80</td>
<td>24</td>
<td>14 (58.3)</td>
<td>10 (41.7)</td>
</tr>
<tr>
<td>Ki-67 index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>23</td>
<td>14 (60.9)</td>
<td>9 (39.1)</td>
</tr>
<tr>
<td>≥10</td>
<td>30</td>
<td>26 (86.7)</td>
<td>4 (13.3)</td>
</tr>
</tbody>
</table>
sequences for human β-actin were 5’-CAC GAT GGA GGG GCC CTC ATC-3’ (forward) and 5’-TAA AGA CCT CTA TGC CAA CAC AGT-3’ (reverse).

**Western blotting**

Western blot analysis was performed on 50 μg of protein lysates from each sample according to a standard protocol [19] using anti-KIF14 (ab71155, 1:2,000), anti-pAKT (S473, ab81283, 1:5,000; T308, ab66134, 1:3,000), anti-AKT (ab32505, 1:5,000), anti-active + pro-caspase 3 (ab13847, 1:2,000), anti-cleaved PARP (ab4830, 1:2,000) and anti-PARP (ab6079, 1:400) antibodies, followed by incubation with secondary horseradish peroxidase antibody (ab6721, 1:3,000) and detection with the Enhanced Chemiluminescence Kit (Amersham Pharmacia Biotech). Mouse monoclonal anti-β-actin (ab75186, 1:1,000) was used as the loading control. All antibodies were purchased from Abcam.

**Immunofluorescence/confocal microscopy**

Adherent U251 glioma cells were cultured on sterile cover glasses in DMEM media with 10% FBS. The cells were fixed with 2% paraformaldehyde, permeabilized with 0.2% Triton-X and incubated with anti-KIF14 (ab71155, 1:1,000; Abcam) for 2 h in a humidified chamber at 37°C. The slides were washed three times in PBS and incubated with secondary antibodies containing mixtures of cy3-conjugated anti-rabbit IgG (ab6939, 1:1,000; Abcam) for 60 min. Finally, the cells were washed three times in PBS and mounted with ProLong Gold antifade reagent (Invitrogen, Camarillo, CA, USA). Under certain circumstances, cells were counterstained with the blue nuclear dye Hoechst 33258. Samples were visualized using a Zeiss LSM 5 PASCAL laser scanning confocal microscope. For α-tubulin/DAPI staining, cells were stained with an anti-α-tubulin (ab71155, 1:1,000; Abcam), followed by an anti-rabbit Alexa 488 secondary antibody (ab150077, 1:100; Abcam), and nuclei visualized by DAPI (Sigma, St. Louis, MO, USA). The binucleated cell fraction was calculated in five fields for each group.

**Constructs and transfection**

Chemically synthesized KIF14 siRNA were purchased from Dharmacon/Thermo Scientific (si-KIF14-1: J-00319-06, si-KIF14-2: J-00319-05). Unless specified, si-KIF14 refers to J-00319-06. In vitro transient transfection was performed using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol.

**Cell proliferation assay**

Cell proliferation was determined by the 3-(4, 5,-dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide (MTT) assay. Cells were plated onto 96-well culture plates and cultured overnight for cell attachment. At daily intervals (24, 48, 72, 96, and 120 h), the number of viable cells was determined by MTT assay as described previously [20, 21]. Absorbance was measured at 570 nm on a microplate reader. Three independent experiments were performed.

**Colony formation assay**

Substrate-independent cell proliferation was determined by soft agar colony formation assays performed in 6-well plates with a 1.5-mL bottom layer and 0.5-mL top layer containing 5.1 mg/mL agar (Difco Laboratories, Detroit, MI) in culture medium (DMEM plus supplements). Cells (1×10^4 / well) were dispersed as a single cell suspension in culture medium with 3.4 mg/mL agar, overlaid onto the bottom agar layer, and covered by the top layer. Cells were incubated for 2 to 3 h at room temperature and then at 37°C under 5% CO₂. The top layer was covered with 400 μL of fresh culture medium every second day. Colony formation was quantified after 10 days using Giemsa staining.

**Apoptosis assay**

The rate of apoptosis was assessed using a MEBCYTO Apoptosis Kit (Medical and Biological Laboratories Co., Ltd, Aichi, Japan) according to the manufacturer’s instructions. In brief, 1×10^5 cells were trypsinized, washed with PBS, and stained with Annexin V-fluorescein isothiocyanate (FITC) and PI in the dark for 15 min at room temperature. The stained cells were then analyzed by flow cytometry (BD FACS Calibur, Becton Dickinson, San Jose, CA). The frequency of Annexin V-positive apoptotic cells was expressed as a percentage of the total number of cells counted.
Cell cycle assay

SiRNA-transfected cells and untransfected control cells were trypsinized, collected, washed, and suspended in cold PBS. On the day of analysis, cells were centrifuged at 1,000 rpm for 5 min, resuspended in 0.5 mL PBS, fixed in 4.5 mL 70% ice-cold ethanol, and stored at 4°C. The cell suspension was then incubated in 0.2 mg/mL propidium iodide (PI) containing 0.1% Triton X-100 and RNase A (1 mg/mL, both from Sigma) in the dark for 30 min at room temperature. Cell cycle distribution was determined using fluorescence-activated cell sorting (FACS) analysis (FACSCalibur, BD Biosciences).

Nude mouse tumor xenograft model and treatment

U251 glioma cells were subcutaneously injected into 5-week-old female nude mice. When the tumor volume reached 50 mm³, the mice were randomly divided into four groups (n = 5 per group). Each group was treated with KIF14 siRNA or nonsense siRNA through local injection of the xenograft tumor at multiple sites. Tumor size was measured every 3 days post injection, and the total volume was calculated using the formula: volume = length × width²/2 [22, 23].

Statistics

All data were expressed as the mean ± standard deviation (SD) of three independent experiments. Comparisons between two groups were performed using the Student’s t-test, and comparisons between three or more groups were performed using analysis of variance (ANOVA) followed by Dunnett’s t-test. Immunoblot bands were visualized and quantified by ImageJ software (NIH, USA). p < 0.05 was considered statistically significant.

Results

KIF14 is upregulated in astrocytoma tissues and glioblastoma cell lines

Quantitative real time PCR analysis showed that KIF14 expression levels were significantly higher in malignant (n = 31) and low-grade (n = 22) astrocytomas than in normal brain tissues (n = 5) (p < 0.01) (Fig. 1A). Western blot analysis confirmed that KIF14 expression levels increased in correlation with the severity of astrocytoma (Fig. 1B). KIF14 expression was significantly higher in glioblastoma cell lines than in the normal astrocytes (NHA) (Fig. 1C).

The cellular localization of the KIF14 protein in human astrocytoma tissues was examined by immunohistochemistry. As shown in Fig. 2A, KIF14 immunoreactivity was predominantly detected in the cytoplasm.

Fig. 1. Expression of KIF14 in human glioma tissues and cell lines. (A) qPCR analysis of KIF14 expression in high grade (WHO III and IV) and low grade (WHO I and II) glioma samples. (B) Western blot analysis of KIF14 expression in gliomas of different grades and normal brain tissues (NC). (C) Western blot analysis of KIF14 protein levels in various glioma cell lines and normal astrocytes (NHA). * p < 0.05, ** p < 0.01.
and/or nucleus of malignant astrocytoma tissues (d, e), whereas weakly positive staining for KIF14 was observed in normal brain tissues (a). Statistical analysis showed that the KIF14 labeling index was significantly higher in high-grade astrocytomas than in low-grade tumors (16.67 ± 6.89% vs. 4.95 ± 2.92%, respectively; \( p < 0.01 \)) and normal controls (16.67 ± 6.89% vs. 0.60 ± 0.41%, respectively; \( p < 0.01 \)). The semi-quantitative results of KIF14 and Ki-67 immunostaining are shown in Fig. 2B and Fig. 2C. KIF14 staining was positively correlated with proliferative activity as indicated by Ki-67 staining (\( p < 0.01; r = 0.67, \) Spearman’s correlation coefficient) (Fig. 2D). Immunofluorescence/confocal microscopy analysis showed that KIF14 localized to the cytoplasm and/or nucleus of U251 glioma cells (Fig. 2E), confirming the immunohistochemical detection of KIF14 in the cytoplasm and/or nucleus of astrocytoma cells.

The associations of KIF14 expression with the clinicopathological features of gliomas are summarized in Table 1. The high level of KIF14 expression was significantly correlated...
Fig. 3. Effects of KIF14 expression on glioblastoma cell growth and cell cycle. Western blot analysis of KIF14 expression (A) and MTT cell proliferation assays (B) in U251 and U87 glioblastoma cells transfected with siRNA targeting KIF14 or scrambled siRNA for 24 h. (C) Colony formation assays in U251 and U87 glioblastoma cells showed that KIF14 knockdown resulted in a significant decrease in colony number compared with the control groups. (D) Effect of KIF14 knockdown on tumor growth in vivo. Left panel: Final tumor photographs at 35 days post-subcutaneous injection. Right panel: average tumor volume during treatment. The bars represent the means ± SD of five mice per group.

Effects of KIF14 inhibition on cell proliferation in vitro and xenograft tumor formation in vivo

The effect of two KIF14 siRNAs was examined by western blotting, which showed that the protein levels of KIF14 were significantly lower in KIF14-siRNA transfected cells than in uninfected glioma cells and negative controls, and si-KIF14-1 suppressed KIF14 expression most efficiently (Fig. 3A). Therefore, all of the downstream assays were performed using si-KIF14-1 (hereafter referred to as si-KIF14). The results of MTT assay showed that the rate of proliferation of U251 and U87 cells was significantly lower in KIF14-siRNA transfected cells than in uninfected parental cells or negative controls (Fig. 3B). Colony formation assays further demonstrated that knockdown of KIF14 in U251 or U87 cells significantly inhibited colony formation (Fig. 3C). The effect of KIF14 silencing on tumor growth inhibition was confirmed in vivo in a U251 xenograft model. At the termination of the study, tumor volume was significantly lower in si-KIF14 tumors than in si-scramble control tumors (Fig. 3D).
Effects of KIF14 inhibition on cell cycle progression

The effect of KIF14 silencing on cell cycle progression was examined by measuring the DNA content in PI-stained cells by flow cytometry and counting the fraction of cells in G1, S and G2/M phases (Fig. 4A). The fraction of cells in G2/M phase was significantly higher in glioma cell lines infected with KIF14-siRNA (34.3% in U251 cells and 33.5% in U87 cells) than in uninfected cells (19.5% in U251 cells and 17.6% in U87 cells), indicating that silencing of KIF14 by siRNA induced the G2/M phase arrest in both U251 and U87 cells. Since KIF14 is involved in mitotic spindle assembly [10], the effect of KIF14 silencing on cytokinesis was further evaluated by α-tubulin/DAPI staining in U251 cells (Fig. 4B). Besides, the binucleate cell fraction was measured, and the fraction of binucleate cells in the KIF14-siRNA transfected cells was significantly higher than that in untransfected and si-scramble transfected cells (36.5% vs. 14.2% and 12.1%, *p < 0.05; Fig. 4C), suggesting that cells with KIF14 silencing more prone to cytokinesis failure.

KIF14 inhibition induces apoptosis via inactivation of Akt kinase

AnnexinV/PI staining showed a significantly greater number of apoptotic cells in glioblastoma cell suspensions infected with siRNA against KIF14 than in the control groups.
To further explore the mechanisms by which KIF14 depletion induces apoptosis of glioblastoma cells, the activity of signaling pathways associated with apoptosis was examined by western blotting in cells subjected to KIF14 knockdown. As shown in Fig. 6, suppression of KIF14 expression caused a time-dependent downregulation of both cleaved caspase-3 and cleaved PARP, as well as phosphorylated or activated Akt at Ser473 and T308 in U251 and U87 cell lines. These results indicate that KIF14 silencing may inhibit cell survival by suppressing AKT activation in glioblastoma cells.

(Fig. 5). To further explore the mechanisms by which KIF14 depletion induces apoptosis of glioblastoma cells, the activity of signaling pathways associated with apoptosis was examined by western blotting in cells subjected to KIF14 knockdown. As shown in Fig. 6, suppression of KIF14 expression caused a time-dependent downregulation of both cleaved caspase-3 and cleaved PARP, as well as phosphorylated or activated Akt at Ser473 and T308 in U251 and U87 cell lines. These results indicate that KIF14 silencing may inhibit cell survival by suppressing AKT activation in glioblastoma cells.

Discussion

KIF14 plays important roles in cell cycle progression and mitosis, and deregulation of KIF14 has been implicated in the development and progression of several human malignancies. In the present study, we examined the significance of KIF14 in the progression of malignant astrocytoma in vitro and in vivo. Our results showed that KIF14 is overexpressed in astrocytoma and associated with the degree of malignancy, and KIF14 expression is correlated with proliferative activity. Knockdown experiments showed that suppression of KIF14 inhibits cell proliferation and induces apoptosis through the inactivation of AKT signaling.

KIF14 was initially cloned in 1994 and since then shown to be an important molecular motor characterized by a C-terminal citron kinase binding domain and an N-terminal motor domain that shows a distinct mechanism of binding to microtubules [24, 25]. KIF14 has been referred to as an oncogenic kinesin because it is overexpressed in many cancers
and is correlated with poor prognosis [26-28]. KIF14 overexpression in lung and breast cancer predicts patient outcome [29, 30], and KIF14 is overexpressed in primary human retinoblastoma, in particular in older patients [31]. In ovarian cancer, high KIF14 expression predicts poor outcome and is associated with increased recurrence rates [32]. However, the mechanism by which KIF14 mediates tumorigenesis is not clear, although it is thought to be related to its role in mitosis. KIF14 expression varies during the cell cycle, with peak expression in S phase, and silencing of KIF14 produces distinct phenotypes depending on the degree of knockdown of the kinesin [10].

The involvement of KIF14 in glioma development or progression was demonstrated in a study that showed that KIF14 is upregulated at the transcriptional level in gliomas, and its overexpression is associated with advanced pathological grade, low Karnofsky performance score, high mitotic and Ki-67 indexes, and poor survival of patients [18]. These results are consistent with the findings of the present study showing that KIF14 expression is correlated with Ki-67 immunostaining in glioma cell lines. Furthermore, KIF14 knockdown inhibited cell proliferation, induced G2/M phase arrest, promoted apoptosis and inhibited tumor growth in vivo. In hepatocellular carcinoma (HCC) cells, knockdown of KIF14 suppressed cell proliferation, caused failure of cytokinesis, and downregulated cyclins E1, D1 and B1, whereas KIF14 overexpression promoted cell proliferation [14]. These effects were found to be mediated by the modulation of the expression of Skp2 and Cks1, which target p27Kip1 for degradation by the 26S proteasome. In another recent study, KIF14 was found to be overexpressed in HCC and associated with tumor grade, and silencing of KIF14 induced apoptosis by inactivating the phosphatidylinositol 3-kinase-Akt (PI3K/AKT) signaling pathway.

**Fig. 6.** Effects of KIF14 siRNA on AKT activation in glioblastoma cell lines. Western blot analysis of KIF14, pAKT (S473, T308) and total AKT, cleaved and total caspase-3, cleaved and total PARP in response to KIF14 silencing for different times in U251 (A) and U87 (B) cells.
pathway [33]. The results of the present study support the findings in HCC by showing that KIF14 knockdown inhibited the S473 and T308 phosphorylation of AKT in glioma cells, suggesting a mechanism underlying the tumorigenic effect of KIF14 in astrocytoma. Similar results were obtained in triple negative breast cancer, where KIF14 knockdown inhibited the expression of pAKT S473 and pAKT T308, indicating that KIF14 plays a role in the activation of PI3K/AKT signaling in breast cancer [34]. Taken together with previous findings, our results suggest that KIF14 could be an attractive therapeutic target for the treatment of glioma, which warrants further investigation into the effects of KIF14 knockdown and the underlying mechanisms in in vitro and in vivo models.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 30930094), National Nature Science Foundation of Shanghai (No.15ZR1414500) and National Natural Science Foundation of China for Youth (No. 81302188).

Disclosure Statement

The authors declare no competing interests.

References


27 Corson TW, Huang A, Tsao MS, Gallie BL: KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 2005;24:4741-4753.


